Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T15:27:16.626Z Has data issue: false hasContentIssue false

Drugs—A Tool for Research in Psychiatry

Published online by Cambridge University Press:  08 February 2018

John C. Saunders*
Affiliation:
Rockland State Hospital, Orangeburg, N.Y., and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York City

Extract

The history of medicine reveals man's search for drugs to ease his diseases and possibly cure them. Advances have been made pharmacologically in the treatment and prevention of many infectious diseases. While psychiatry has benefited from these discoveries in the treatment of certain infections of the central nervous system, in general, the treatment of psychiatric diseases remains largely empirical. The psychopharmacologic treatment of psychiatric diseases continues to be based on the presenting symptom-complex of the patient; this is because the aetiology is still unknown, for in reality our explanations do not explain. The phrenotropic drugs currently used in psychiatry are important for their pharmacodynamic effect since they change the cellular environment in which mental processes are maintained. Pharmacodynamic research in psychiatry has revealed possible neuroanatomical sites and many biochemical effects of these drugs. The specific correlation of these findings with clinical effects is lacking. When this is accomplished, it is probable that better drugs will be developed.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Saunders, J. C., “Clinical implications of neurochemistry in psychiatry”. Presented at Ohio State Medical Association, Neurology Section, April, 1959. Columbus, Ohio.Google Scholar
2. Gosline, E., Bluestone, H., and Saunders, J. C., “ β-Phenylisopropyl Hydrazine (Catron) and its Use in Psychoses”, J. Clin. Ex. Psychopath, 1960, 21, No. 3.Google Scholar
3. Saunders, J. C., “Discussion: Conference on amine oxidase inhibitors”, Ann. N.Y. Acad. Sci., 1959, 88, Art. 3, 719.Google Scholar
4. Idem, Psychic Energizers: A Source of Psychopharmacological Theories. A Pharmacologic Approach to the Study of the Mind, 1959. Springfield, Ill.: C. C. Thomas, p. 379.Google Scholar
5. Schayer, R. W., “Relationship of stress-induced histidine decarboxylase to circulatory homeostasis and shock”, Science, 1960, 131, 226.CrossRefGoogle Scholar
6. Saunders, J. C., “Some chemical concepts in psychosomatic medicine”. Transactions of the Fifth Annual Meeting of the Academy of Psychosomatic Medicine, 1958, 103.Google Scholar
7. Knox, W. E., “Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary adrenal system”, Brit. J. Exptl. Pathol., 1951, 32, 462.Google Scholar
8. Kothari, N. J., Saunders, J. C., and Kline, N. S., “Effect of phenothiazines and hydrazines on pituitary-adrenal response”. Submitted for publication.Google Scholar
9. Saunders, J. C., Etiology of Psychosis Theorized from Drug Actions. Psycho pharmacology Frontiers, 1959, Boston: Little, Brown & Co., p. 405.Google Scholar
10. Idem , “Chelation—An integrative chemical concept of psychoses” (Abstract). Chemical Concepts of Psychosis, 1958, McDowell, Obolensky, N.Y., p. 156.Google Scholar
11. Pullman, B., and Pullman, A., “Electron-donor and -acceptor properties of biologically important purines, pyrimidines, pteridines, flavins and aromatic amino acids”, Proc. Nat. Acad. Sci., U.S., 1958, 44, 1197.CrossRefGoogle Scholar
12. Isenberg, I., and Szent-Gyorgyi, A., “Free radical formation in riboflavin complexes, Proc. Nat. Acad. Sci., U.S., 1958, 44, 857.CrossRefGoogle ScholarPubMed
13. Clapp, L. B., “Chemistry of the coordination compounds”, Organic Molecular Compounds (Chapter 17): ACS monograph series No. 131, 1956, New York: Rheinhold.Google Scholar
14. Mulliken, R. S., “Molecular compounds and their spectra. II. J. Am. Chem. Soc., 1952, 74, 811.CrossRefGoogle Scholar
15. Michaelis, L., Oxydations-reductions Potentiale, 1933. Berlin: Jules Springer.Google Scholar
16. “Free radicals as intermediate steps in the oxidation of organic compounds”, Ann. New York Acad. Sci, 1940, 40, 37.Google Scholar
17. Ball, E. G., “Role of flavoproteins in biological oxidations”, Symposia on Quant. Biol., 1939, 7, 100.CrossRefGoogle Scholar
18. Saunders, J. C., Lourie, I., and Chipkiewicz, H., “Biopsychiatry: Some Alterations of the Intermediary Metabolism in Psychoses”. Presented at the Sixth Bahamas Medical Conference, Nassau, Bahamas. 8–14 December, 1958.Google Scholar
19. Akerfeldt, S., “Oxidation of N, N-dimethyl paraphenylene diamine by serum from patients with mental disease”, Science, 1957, 125, 117.CrossRefGoogle Scholar
20. Saunders, J. C., and Chipkiewicz, H., “Studies of ceruloplasmin in schizophrenics and normal controls”, J. of Clin. and Exp. Psychopath., 1959, 20, No. 1, p. 7.Google Scholar
21. McDonald, R. K., Ceruloplasmin and Schizophrenia. Chemical Concepts of Psychosis, 1958. New York: McDowell, Obolensky, p. 230.Google Scholar
22. Nielsen, L. O., and Lehninger, A. C., “Phosphorylation coupled to the oxidation of ferrocytochrome c”, J. Biol. Chem., 1955, 215, 555.CrossRefGoogle Scholar
23. Cohen, H. P., and Cohen, M. M., “Depression of central nervous system activity”, Psycho pharmacology-Progress in Neurobiology: 1958, 3. New York: Hueber-Harper, p. 47.Google Scholar
24. Zatman, L. J., Kaplan, N. O., Colowick, S. P., and Ciotti, M. M., “The isolation and properties of the isonicotinic acid hydrazide analogue of diphosphopyridine nucleotide”, J. Biol. Chem., 1954, 209, 467.CrossRefGoogle Scholar
25. Winder, F. G., and Denneny, J. M., “Metal-catalyzed auto-oxidation of isoniazid”, Blochem. J., 1959, 73, No. 3, 500.Google Scholar
26. Lagnado, J. R., and Sourkes, T. L., “Inhibition of amine oxidase by metal ions and by sulfhydryl compounds”, Canad. J. Biochem. and Physiol., 1956, 34, 1185.CrossRefGoogle Scholar
27. Idem , and Sourkes, T. L., “Enzymatic reduction of tetrazolium salts by amines”, Canad. J. Biochem. and Physiol., 1956, 34, 1095.Google Scholar
28. Karreman, G., Isenberg, I., and Szent-Gyorgyi, A., “On the mechanism of action of chlorpromazine”, Science, 1959, 130, 1191.CrossRefGoogle Scholar
29. Henderson, L. M., Weinstock, I. M., and Ramasarma, G. B., “Effect of deficiency of B vitamins on the metabolism of tryptophan by the rat”, J. Biol. Chem., 1951, 189, 19.CrossRefGoogle Scholar
30. Charconnet-Harding, F., Dalgliesh, C. E., and Neuberger, A., “The relation between riboflavin and tryptophan metabolism studied in the rat”, Biochem. J., 1953, 53, 513.CrossRefGoogle Scholar
31. Kurokawa, M., Naruse, H., Kato, M., Yake, T., and Haba, R., “Action of chlorpromazine on the respiratory system of guinea-pig brain cell-free preparations”, Folia Psychiatrica et Neurologica Japonica, 1957, 10, 354.Google Scholar
32. Lehninger, A. L., “Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide”, J. Biol. Chem., 1951, 190, 345.CrossRefGoogle Scholar
33. Burton, R. M., Kaplan, N. O., Goldin, A., Leitenberg, M., Sodd, M. A., and Humphreys, S. R., “Effects of reserpine and promazine on DPN synthesis in liver”, Science, 1958, 127, 30.CrossRefGoogle Scholar
34. Lindan, O., Quastel, J. H., and Sved, S., “Biochemical studies of chlorpromazine. II”, Canad. J. Biochem. Physiol., 1957, 35, 1145.CrossRefGoogle Scholar
35. Saunders, J. C., “Round Table: Clinical clues as to mode of action of the ataractic drugs”, The Psychiatric Quarterly, 1958, 32, 64.Google Scholar
36. Idem , “Discussion: Chemical Concepts of Psychosis”, 1958. New York: McDowell, Obolensky, p. 437.Google Scholar
37. Lundigardh, H., “Salts and respiration”, Nature, 1960, 185, 70.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.